Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 23 | 2020 | 828 | 3.240 |
Why?
|
| Hallucinations | 9 | 2023 | 61 | 1.850 |
Why?
|
| Emotions | 2 | 2015 | 79 | 0.530 |
Why?
|
| Visual Pathways | 2 | 2014 | 5 | 0.520 |
Why?
|
| Amygdala | 1 | 2015 | 40 | 0.500 |
Why?
|
| Blindness | 1 | 2014 | 12 | 0.460 |
Why?
|
| Contrast Sensitivity | 3 | 2002 | 7 | 0.400 |
Why?
|
| Brain | 3 | 2023 | 1647 | 0.390 |
Why?
|
| Humans | 28 | 2023 | 25991 | 0.370 |
Why?
|
| Placebo Effect | 1 | 2008 | 19 | 0.310 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2008 | 3 | 0.310 |
Why?
|
| Placebos | 1 | 2008 | 66 | 0.310 |
Why?
|
| Tauopathies | 1 | 2008 | 20 | 0.300 |
Why?
|
| Depressive Disorder | 1 | 2008 | 167 | 0.290 |
Why?
|
| Fetal Tissue Transplantation | 2 | 2000 | 25 | 0.280 |
Why?
|
| Dystonia | 3 | 1997 | 15 | 0.270 |
Why?
|
| Head | 1 | 2006 | 22 | 0.260 |
Why?
|
| Multiple System Atrophy | 1 | 2006 | 36 | 0.250 |
Why?
|
| Visual Perception | 2 | 2005 | 35 | 0.250 |
Why?
|
| Color Vision Defects | 2 | 2002 | 4 | 0.250 |
Why?
|
| Myositis | 1 | 2006 | 34 | 0.250 |
Why?
|
| Pain | 1 | 2008 | 383 | 0.240 |
Why?
|
| Age of Onset | 2 | 2003 | 92 | 0.240 |
Why?
|
| Brain Chemistry | 1 | 2005 | 41 | 0.240 |
Why?
|
| Cerebral Cortex | 2 | 2020 | 159 | 0.230 |
Why?
|
| Sick Role | 1 | 2003 | 14 | 0.220 |
Why?
|
| Vision Disorders | 2 | 2005 | 20 | 0.220 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 31 | 0.210 |
Why?
|
| Models, Biological | 1 | 2005 | 304 | 0.210 |
Why?
|
| Space Perception | 1 | 2002 | 24 | 0.200 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 138 | 0.200 |
Why?
|
| Levodopa | 4 | 2009 | 47 | 0.190 |
Why?
|
| Middle Aged | 11 | 2008 | 8511 | 0.190 |
Why?
|
| Aged | 12 | 2008 | 8719 | 0.190 |
Why?
|
| Subthalamic Nucleus | 1 | 2000 | 20 | 0.180 |
Why?
|
| Electric Stimulation Therapy | 1 | 2000 | 41 | 0.180 |
Why?
|
| Axons | 1 | 2020 | 24 | 0.180 |
Why?
|
| Adrenal Glands | 1 | 2000 | 6 | 0.170 |
Why?
|
| Mitochondria | 1 | 2020 | 57 | 0.170 |
Why?
|
| Sleep Wake Disorders | 3 | 2009 | 102 | 0.170 |
Why?
|
| Corpus Striatum | 1 | 2000 | 61 | 0.170 |
Why?
|
| Huntington Disease | 1 | 2000 | 50 | 0.160 |
Why?
|
| Botulinum Toxins | 2 | 1997 | 8 | 0.160 |
Why?
|
| Biological Evolution | 1 | 2019 | 9 | 0.160 |
Why?
|
| Movement Disorders | 2 | 1998 | 90 | 0.160 |
Why?
|
| Substantia Nigra | 1 | 2000 | 113 | 0.160 |
Why?
|
| Male | 12 | 2008 | 13999 | 0.160 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1998 | 3 | 0.160 |
Why?
|
| Color Perception | 1 | 1998 | 5 | 0.160 |
Why?
|
| Mental Disorders | 1 | 2000 | 126 | 0.150 |
Why?
|
| Muscle Relaxants, Central | 1 | 1997 | 3 | 0.150 |
Why?
|
| Baclofen | 1 | 1997 | 3 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 1998 | 17 | 0.150 |
Why?
|
| Neurons | 1 | 2020 | 309 | 0.140 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 1996 | 1 | 0.140 |
Why?
|
| Genes | 1 | 1996 | 4 | 0.140 |
Why?
|
| Globus Pallidus | 1 | 1996 | 11 | 0.130 |
Why?
|
| Genetic Variation | 1 | 1996 | 96 | 0.130 |
Why?
|
| Phylogeny | 1 | 2015 | 45 | 0.130 |
Why?
|
| Follow-Up Studies | 4 | 2006 | 1711 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 1997 | 116 | 0.120 |
Why?
|
| Superior Colliculi | 1 | 2014 | 2 | 0.120 |
Why?
|
| Basal Ganglia | 2 | 2008 | 15 | 0.110 |
Why?
|
| Female | 9 | 2008 | 14365 | 0.110 |
Why?
|
| Adrenal Medulla | 1 | 1993 | 7 | 0.110 |
Why?
|
| Lewy Bodies | 1 | 2014 | 193 | 0.100 |
Why?
|
| Thalamus | 1 | 1992 | 16 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 1140 | 0.100 |
Why?
|
| Dopamine | 2 | 2008 | 79 | 0.100 |
Why?
|
| Dopamine Agents | 1 | 1992 | 16 | 0.100 |
Why?
|
| Risk Factors | 3 | 2005 | 2242 | 0.090 |
Why?
|
| Vision Tests | 2 | 2002 | 5 | 0.090 |
Why?
|
| Antiparkinson Agents | 2 | 2003 | 65 | 0.090 |
Why?
|
| Illusions | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2009 | 12 | 0.080 |
Why?
|
| Neurotransmitter Agents | 1 | 2009 | 16 | 0.080 |
Why?
|
| Disease Progression | 2 | 2003 | 685 | 0.080 |
Why?
|
| Antipsychotic Agents | 1 | 2009 | 57 | 0.080 |
Why?
|
| Opioid Peptides | 1 | 2008 | 7 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 41 | 0.080 |
Why?
|
| Cognition Disorders | 2 | 2009 | 991 | 0.080 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2008 | 27 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 84 | 0.080 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 2 | 0.070 |
Why?
|
| Electromyography | 1 | 2006 | 59 | 0.060 |
Why?
|
| Animals | 2 | 2009 | 3387 | 0.060 |
Why?
|
| Biopsy | 1 | 2006 | 199 | 0.060 |
Why?
|
| Reality Testing | 1 | 2003 | 2 | 0.050 |
Why?
|
| Adult | 3 | 2003 | 7354 | 0.050 |
Why?
|
| Dementia | 1 | 2008 | 532 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2006 | 358 | 0.050 |
Why?
|
| Self Care | 1 | 2003 | 92 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2003 | 259 | 0.050 |
Why?
|
| Social Support | 1 | 2003 | 179 | 0.050 |
Why?
|
| Logistic Models | 1 | 2003 | 360 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 713 | 0.050 |
Why?
|
| Prevalence | 1 | 2003 | 433 | 0.050 |
Why?
|
| Comorbidity | 1 | 2003 | 466 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2003 | 324 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2003 | 547 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2003 | 621 | 0.040 |
Why?
|
| Syndrome | 1 | 2000 | 73 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 929 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 4674 | 0.040 |
Why?
|
| Sleep, REM | 1 | 1998 | 10 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 1998 | 31 | 0.040 |
Why?
|
| Violence | 1 | 1998 | 31 | 0.040 |
Why?
|
| Botulinum Toxins, Type A | 1 | 1997 | 8 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1997 | 5 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 1997 | 22 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2002 | 1649 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 170 | 0.040 |
Why?
|
| Muscle Spasticity | 1 | 1997 | 4 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 315 | 0.030 |
Why?
|
| Motor Neurons | 1 | 1996 | 17 | 0.030 |
Why?
|
| Models, Neurological | 1 | 1996 | 24 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 1996 | 42 | 0.030 |
Why?
|
| Registries | 1 | 1996 | 171 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 1997 | 1342 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 1993 | 9 | 0.030 |
Why?
|
| Oxidopamine | 1 | 1993 | 10 | 0.030 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 1993 | 18 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 1993 | 14 | 0.030 |
Why?
|
| Lactose | 1 | 1992 | 1 | 0.030 |
Why?
|
| Methylcellulose | 1 | 1992 | 2 | 0.030 |
Why?
|
| Lisuride | 1 | 1992 | 2 | 0.030 |
Why?
|
| Pergolide | 1 | 1992 | 3 | 0.030 |
Why?
|
| Apomorphine | 1 | 1992 | 4 | 0.030 |
Why?
|
| Bromocriptine | 1 | 1992 | 5 | 0.030 |
Why?
|
| Oxazines | 1 | 1992 | 5 | 0.030 |
Why?
|
| Receptors, Dopamine | 1 | 1992 | 8 | 0.030 |
Why?
|
| Functional Laterality | 1 | 1992 | 62 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1992 | 253 | 0.020 |
Why?
|
| Tremor | 1 | 1992 | 117 | 0.020 |
Why?
|
| Parasympatholytics | 1 | 1990 | 3 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1992 | 298 | 0.020 |
Why?
|
| Dopamine Antagonists | 1 | 1990 | 5 | 0.020 |
Why?
|
| Neuromuscular Diseases | 1 | 1990 | 4 | 0.020 |
Why?
|
| Neurosurgery | 1 | 1990 | 31 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1990 | 342 | 0.020 |
Why?
|
| Time Factors | 1 | 1992 | 1361 | 0.020 |
Why?
|
| Caregivers | 1 | 1998 | 145 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1998 | 1066 | 0.010 |
Why?
|